SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, several genetic variants are associated with drug transport genes, such as ABCB 11263 (TT), (CT/TT); ABCB 2677 (TT/TA), (G); ABCB 3435 (TT), (CC), ABCG 234 (G>A), ABCG 421 (C>A), SLC22A1 rs3798168, rs628031, IVS7+ 850 (C>T), SLC22A1 480 (C>G), SLC22A1 401 (G/A), SLC22A4 rs1050152, SLCO1A2 361 (GG), SLCO1B3 334 (GG), (TT); SLCO1B3 699 (GG), ABCA3 4548–91 (CC/CA), which are associated with mediating drug resistance, increased drug clearance, and decreased treatment outcomes of TKIs in CML (reviewed comprehensively in reference [23]).